CA3246810A1 - Kras inhibitors - Google Patents
Kras inhibitorsInfo
- Publication number
- CA3246810A1 CA3246810A1 CA3246810A CA3246810A CA3246810A1 CA 3246810 A1 CA3246810 A1 CA 3246810A1 CA 3246810 A CA3246810 A CA 3246810A CA 3246810 A CA3246810 A CA 3246810A CA 3246810 A1 CA3246810 A1 CA 3246810A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- pharmaceutically acceptable
- alkyl
- acceptable salt
- kras
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323607P | 2022-03-25 | 2022-03-25 | |
| US63/323,607 | 2022-03-25 | ||
| US202263406906P | 2022-09-15 | 2022-09-15 | |
| US63/406,906 | 2022-09-15 | ||
| US202263386404P | 2022-12-07 | 2022-12-07 | |
| US63/386,404 | 2022-12-07 | ||
| PCT/US2023/016257 WO2023183585A1 (en) | 2022-03-25 | 2023-03-24 | Kras inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246810A1 true CA3246810A1 (en) | 2023-09-28 |
Family
ID=86331239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246810A Pending CA3246810A1 (en) | 2022-03-25 | 2023-03-24 | Kras inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12351591B2 (https=) |
| EP (1) | EP4499233A1 (https=) |
| JP (2) | JP7676677B2 (https=) |
| KR (2) | KR102847563B1 (https=) |
| CN (1) | CN119095853A (https=) |
| AU (1) | AU2023241055A1 (https=) |
| CA (1) | CA3246810A1 (https=) |
| CL (1) | CL2024002874A1 (https=) |
| CO (1) | CO2024012604A2 (https=) |
| DO (1) | DOP2024000186A (https=) |
| IL (1) | IL315782A (https=) |
| JO (1) | JOP20240210A1 (https=) |
| MX (1) | MX2024011631A (https=) |
| PE (1) | PE20251071A1 (https=) |
| TW (2) | TWI852436B (https=) |
| WO (1) | WO2023183585A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2024206747A1 (en) * | 2023-03-30 | 2024-10-03 | Eli Lilly And Company | Kras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| EP4688792A1 (en) * | 2023-03-31 | 2026-02-11 | Eli Lilly and Company | Kras inhibitors |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024323424A1 (en) | 2023-08-17 | 2026-03-05 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025092798A1 (zh) * | 2023-10-30 | 2025-05-08 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类化合物、其制备方法及其在医药上的应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547457A (zh) * | 2024-04-08 | 2025-12-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 二氫呋喃并[3,4-f]喹唑啉類化合物、其製備方法及其在醫藥上的應用 |
| WO2025214344A1 (zh) * | 2024-04-09 | 2025-10-16 | 上海和誉生物医药科技有限公司 | 一种kras抑制剂及其在药学上的应用 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026059955A1 (en) * | 2024-09-11 | 2026-03-19 | Eli Lilly And Company | (3-((6-(2-amino-benzo[d]thiazol-4-yl)-3-(pyrrolidin-1-yl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)amino)- piperidin-2-one derivatives as kras inhibitors for the treatment of cancer |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| US12600733B2 (en) * | 2024-10-01 | 2026-04-14 | Eli Lilly And Company | KRAS inhibitors |
| WO2026075942A1 (en) * | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10844051B2 (en) | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| HRP20230377T1 (hr) | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
| TW202033518A (zh) * | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| ES2929700T3 (es) | 2019-12-11 | 2022-12-01 | Lilly Co Eli | Inhibidores de KRas g12c |
| EP4161934A1 (en) * | 2020-06-04 | 2023-04-12 | Antengene Discovery Limited | Inhibitors of kras g12c protein and uses thereof |
| CN113880827B (zh) * | 2020-07-03 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| CN116368130A (zh) * | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| US20240166660A1 (en) | 2021-01-15 | 2024-05-23 | Beigene Switzerland Gmbh | Kras g12c inhibitors |
| WO2022184178A1 (en) | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| CA3210383A1 (en) * | 2021-03-12 | 2022-09-15 | Bristol-Myers Squibb Company | Kras inhibitors |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| WO2023061294A1 (zh) | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
-
2023
- 2023-03-24 JP JP2024556680A patent/JP7676677B2/ja active Active
- 2023-03-24 PE PE2024001867A patent/PE20251071A1/es unknown
- 2023-03-24 AU AU2023241055A patent/AU2023241055A1/en active Pending
- 2023-03-24 KR KR1020247035268A patent/KR102847563B1/ko active Active
- 2023-03-24 EP EP23723097.4A patent/EP4499233A1/en active Pending
- 2023-03-24 WO PCT/US2023/016257 patent/WO2023183585A1/en not_active Ceased
- 2023-03-24 US US18/189,713 patent/US12351591B2/en active Active
- 2023-03-24 KR KR1020257020079A patent/KR20250093430A/ko active Pending
- 2023-03-24 IL IL315782A patent/IL315782A/en unknown
- 2023-03-24 CA CA3246810A patent/CA3246810A1/en active Pending
- 2023-03-24 CN CN202380030401.9A patent/CN119095853A/zh active Pending
- 2023-03-24 MX MX2024011631A patent/MX2024011631A/es unknown
- 2023-03-25 TW TW112111395A patent/TWI852436B/zh active
- 2023-03-25 TW TW113108193A patent/TW202438502A/zh unknown
-
2024
- 2024-09-17 CO CONC2024/0012604A patent/CO2024012604A2/es unknown
- 2024-09-20 DO DO2024000186A patent/DOP2024000186A/es unknown
- 2024-09-25 CL CL2024002874A patent/CL2024002874A1/es unknown
- 2024-09-26 JO JOJO/P/2024/0210A patent/JOP20240210A1/ar unknown
-
2025
- 2025-04-30 JP JP2025075148A patent/JP2025118729A/ja active Pending
- 2025-05-29 US US19/222,746 patent/US20250289830A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023241055A1 (en) | 2024-10-10 |
| US20250289830A1 (en) | 2025-09-18 |
| WO2023183585A1 (en) | 2023-09-28 |
| EP4499233A1 (en) | 2025-02-05 |
| CN119095853A (zh) | 2024-12-06 |
| JP7676677B2 (ja) | 2025-05-14 |
| JP2025118729A (ja) | 2025-08-13 |
| KR102847563B1 (ko) | 2025-08-20 |
| PE20251071A1 (es) | 2025-04-10 |
| TW202438502A (zh) | 2024-10-01 |
| JP2025512811A (ja) | 2025-04-22 |
| US12351591B2 (en) | 2025-07-08 |
| US20240043451A1 (en) | 2024-02-08 |
| TW202404572A (zh) | 2024-02-01 |
| KR20240160650A (ko) | 2024-11-11 |
| MX2024011631A (es) | 2024-09-30 |
| IL315782A (en) | 2024-11-01 |
| CL2024002874A1 (es) | 2024-12-20 |
| KR20250093430A (ko) | 2025-06-24 |
| CO2024012604A2 (es) | 2024-12-09 |
| TWI852436B (zh) | 2024-08-11 |
| JOP20240210A1 (ar) | 2024-09-26 |
| DOP2024000186A (es) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102847563B1 (ko) | Kras 억제제 | |
| JP7668908B2 (ja) | Ｋｒａｓ ｇ１２ｄ阻害剤としての置換縮合アジン | |
| WO2025072457A1 (en) | Kras inhibitors | |
| KR20250164300A (ko) | KRas 억제제 | |
| CN113061132B (zh) | 一类稠环内酰胺类化合物、制备方法和用途 | |
| AU2015280138B2 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| KR20250163395A (ko) | KRas 억제제 | |
| JP2024502886A (ja) | がんを処置及び／又は予防するためのｓｏｓ１阻害薬の医薬組合せ | |
| CN111936499A (zh) | Mat2a的杂二环抑制剂和用于治疗癌症的方法 | |
| EA024845B1 (ru) | Замещенные хинолины и их применение в качестве лекарственных средств | |
| TW201315733A (zh) | 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用 | |
| TWI869674B (zh) | 雜芳基衍生化合物及其用途 | |
| EA052362B1 (ru) | Ингибиторы kras | |
| CA3221317C (en) | Substituted fused azines as kras g12d inhibitors | |
| WO2026075945A1 (en) | Kras inhibitors | |
| JP2026052679A (ja) | Ｋｒａｓ阻害剤 | |
| JP2026513780A (ja) | Ｋｒａｓ阻害剤 | |
| WO2026075942A1 (en) | Kras inhibitors | |
| EA041815B1 (ru) | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240925 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240925 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241011 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241011 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241011 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241016 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241119 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20241211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250226 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250319 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250819 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250825 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251103 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251103 |